A Novel Splice-Site Mutation in Angiotensin I-Converting Enzyme (ACE) Gene, c.3691+1G>A (IVS25+1G>A), Causes a Dramatic Increase in Circulating ACE through Deletion of the Transmembrane Anchor by Persu, A. (Alexandre) et al.
A Novel Splice-Site Mutation in Angiotensin I-Converting
Enzyme (ACE) Gene, c.3691+1G.A (IVS25+1G.A),
Causes a Dramatic Increase in Circulating ACE through
Deletion of the Transmembrane Anchor
Alexandre Persu1,2*, Michel Lambert3, Jaap Deinum4, Marta Cossu5,6, Nathalie de Visscher3,
Leonid Irenge7, Jeroˆme Ambroise7, Jean-Marc Minon8, Andrew B. Nesterovitch9,
Alexander Churbanov10, Isolda A. Popova11, Sergei M. Danilov12,13, A. H. Jan Danser14, Jean-Luc Gala7
1 Pole of Cardiovascular Research, Institut de Recherche Expe´rimentale et Clinique, Universite´ Catholique de Louvain, Brussels, Belgium, 2Division of Cardiology, Cliniques
Universitaires Saint-Luc, Universite´ Catholique de Louvain, Brussels, Belgium, 3Division of Internal Medicine, Cliniques Universitaires Saint-Luc, Universite´ catholique de
Louvain, Brussels, Belgium, 4Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands, 5Department of Rheumatology, Radboud
University Medical Center, Nijmegen, The Netherlands, 6Department of Rheumatology, University Medical Center, Utrecht, The Netherlands, 7Center of Applied
Molecular Technologies, Institut de Recherche Expe´rimentale et Clinique, Universite´ catholique de Louvain, Brussels, Belgium, 8Department of Laboratory Medicine,
Transfusion and Thrombosis-Haemostasis Unit, CHR de la Citadelle, Lie`ge, Belgium, 9Department of Dermatology, Rush University, Chicago, Illinois, United States of
America, 10 Biology Department, New Mexico State University, Las Cruces, New Mexico, United States of America, 11 Institute for Chemistry of Life, Northwestern
University, Evanston, Illinois, United States of America, 12 Institute for Personalized Respiratory Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of
America, 13Department of Anesthesiology, University of Illinois at Chicago, Chicago, Illinois, United States of America, 14Division of Pharmacology and Vascular
Medicine, Department of Internal Medicine, Erasmus University, Rotterdam, The Netherlands
Abstract
Background: Angiotensin-converting enzyme (ACE) (EC 4.15.1) metabolizes many biologically active peptides and plays a
key role in blood pressure regulation and vascular remodeling. Elevated ACE levels are associated with different
cardiovascular and respiratory diseases.
Methods and Results: Two Belgian families with a 8-16-fold increase in blood ACE level were incidentally identified. A novel
heterozygous splice site mutation of intron 25 - IVS25+1G.A (c.3691+1G.A) - cosegregating with elevated plasma ACE was
identified in both pedigrees. Messenger RNA analysis revealed that the mutation led to the retention of intron 25 and
Premature Termination Codon generation. Subjects harboring the mutation were mostly normotensive, had no left
ventricular hypertrophy or cardiovascular disease. The levels of renin-angiotensin-aldosterone system components in the
mutated cases and wild-type controls were similar, both at baseline and after 50 mg captopril. Compared with non-affected
members, quantification of ACE surface expression and shedding using flow cytometry assay of dendritic cells derived from
peripheral blood monocytes of affected members, demonstrated a 50% decrease and 3-fold increase, respectively. Together
with a dramatic increase in circulating ACE levels, these findings argue in favor of deletion of transmembrane anchor,
leading to direct secretion of ACE out of cells.
Conclusions: We describe a novel mutation of the ACE gene associated with a major familial elevation of circulating ACE,
without evidence of activation of the renin-angiotensin system, target organ damage or cardiovascular complications. These
data are consistent with the hypothesis that membrane-bound ACE, rather than circulating ACE, is responsible for
Angiotensin II generation and its cardiovascular consequences.
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Introduction
Angiotensin I-converting enzyme (ACE) is a Zn2+ carboxydi-
peptidase enzyme which transforms angiotensin I in angiotensin
II, a potent vasoconstrictor, as well as other biologically active
peptides. Through this metabolic process, ACE plays a key role in
the regulation of blood pressure and also in the development of
vascular pathology and remodeling [1–3]. In man, the gene coding
ACE is mapped on chromosome 17 (17q23). It is 21 kilobases long
and comprises 26 exons and 25 introns [4].
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There are two different isoforms of ACE: somatic ACE, which is
expressed in somatic tissues and testicular ACE, which is restricted
to testes and germinal tissue [5] and generated due to alternative
splicing [4,6–7]. ACE is constitutively expressed on the surface of
endothelial cells, different absorptive epithelial and neuroepithelial
cells [8–13], and cells of the immune system -macrophages and
dendritic cells [14–15]. Somatic ACE mRNA includes all 26 exons
except exon 13 which is spliced, whereas testicular ACE mRNA
includes exons 13 to 26 [4]. Somatic original ACE protein is
constituted of 1306 aminoacids, including the peptide signal
(position 1 to 29) [6], which is removed upon insertion of the
enzyme in the plasma membrane. Both isoforms are plasma
membrane-bound through a transmembrane domain spanning
from valine 1228 to serine 1248, these positions being defined
according to mature somatic ACE, after removal of peptide signal
[16].
Serum ACE originates likely from endothelial cells [17] through
proteolytic cleavage by an unknown secretase [11,17–21]. The
release of soluble ACE in plasma is achieved through cleavage of
Arg1203-Ser1204 peptide bond in the stalk region of ACE, near
the transmembrane segment [20].
In healthy individuals, the circulating ACE level is very stable
[22], as opposed to higher concentrations of circulating ACE in
patients with granulomatous diseases (sarcoidosis in particular) and
Gaucher’s disease [23–25]. During the past decade, different
mutations in somatic ACE have been reported to associate with
high serum ACE levels [26–28].
We report here the identification of a novel splice site mutation
of intron 25 (IVS25+1G.A) of the ACE gene, associated to a
dramatic increase in levels of circulating ACE, without any
apparent harmful effect on human health.
Materials and Methods
Ethics Statement
The study protocol was approved by the Faculty of Medicine
and Health Sciences Research Ethics Committee of the Universite´
catholique de Louvain (Belgium) and the procedures to be
followed were in accordance with institutional guidelines. Adult
subjects gave written informed consent for DNA extraction, blood
analysis and the captopril test. For the single minor participant,
written informed consent was also obtained from both parents.
The consent procedure was approved by the Ethics Committee.
Study Participants
A dramatic increase in circulating ACE level was detected in a
41- year-old Belgian normotensive lady during a thorough work-
up for fatigue. No evidence of sarcoidosis or of other granuloma-
tous diseases was found. Consequently, circulating ACE level and
ACE genotype determination were assessed for the patient, her
daughter and 7 relatives, as well as her husband (used as a control).
Aside of ACE blood tests and genetic testing, a standardized
medical work-up was proposed to all subjects enrolled in this
study, including a detailed interview of past medical history and
current complaints, blood pressure and heart rate measurements,
as well as a determination of circulating components of the renin-
angiotensin-aldosterone system (RAAS), both at baseline and 3
and 6 hours after oral intake of 50 mg captopril. Blood pressure
was measured seated and after three minutes rest using a validated
oscillometric device (OMRON M10-ITH). At each step, 3
measures were recorded at 1-minute-intervals. Baseline levels of
serum creatinine and potassium, and urine protein-to-creatinine
ratio were also determined.
Afterwards, a major elevation of plasma ACE, related to the
same mutation, was also found in another apparently unrelated
Belgian patient. Plasma ACE level was measured and genetic
analysis of ACE was also performed in the index patient and
available relatives, and relevant clinical information was obtained.
Measurement of RAAS Parameters
In the first pedigree, circulating ACE level was measured using
a colorimetric kit (Fujirebio Inc, Tokyo, Japan), with a reference
range of 8.0–26 IU/L [29]. In the second pedigree, circulating
ACE was measured using the ACE kinetic Kit (Bu¨hlmann,
Scho¨nenbuch, Switzerland), with a reference range of 12–68 IU/
L. Alternatively a fluorimetric assay [30–31] was used. Briefly, 20–
40 ml aliquots of serum or plasma, diluted 1/5–1/50 in PBS-BSA
(0.1 mg/ml), were added to 200 ml of ACE substrate (5 mM Hip-
His-Leu or 2 mM Z-Phe-His-Leu), and incubated for the
appropriate time at 37uC. The His-Leu product was quantified
by incubation with O-phthaldialdehyde spectrofluorometrically at
365 nm excitation and 500 nm emission wavelengths.
Total renin concentration was measured with a commercial
immunoradiometric kit (Renin III, Cisbio, Gif-Sur-Yvette, France)
[32]. The measurement was performed before and after the
induction of a conformational change in the prorenin molecule
with renin inhibitor aliskiren (10 mmol/L for 48 hours at 4uC),
enabling renin recognition by active site-directed radiolabeled
antibodies of the Cisbio kit [32].http://circ.ahajournals.org/cgi/
content/full/117/25/3199 - R18-189866#R18-189866 Substrac-
tion of the renin concentration from the total renin concentration
yielded the prorenin concentration. Angiotensinogen was mea-
sured as the maximum quantity of angiotensin (Ang) I that was
generated during incubation with excess recombinant renin. Ang I
and II were measured with sensitive radioimmunoassay [33].
Aldosterone was measured by solid-phase radioimmunoassay [32].
Flow Cytometry of Dendritic Cells with Anti-ACE mAbs
and ACE Shedding
Immature dendritic cells (DC) were generated from 2 individ-
uals with elevated ACE and 2 non-affected family members as
described before [26]. Briefly, peripheral mononuclear cells from
the blood of affected and non-affected individuals were cultured
for 6 days in conditions which generated their differentiation into
immature dendritic cells. After 6 days, cells were harvested,
washed and counted and media used for culture collected. Flow
cytometric analysis was performed with 1 million of DC using
10 mg/ml of the mixture of anti-ACE primary mAbs - i2H5, 9B9
[15] and FITC-conjugated GAM IgG F(ab9)2 (Zymed, San
Francisco, CA) as the secondary antibody on a FACScan flow
cytometer (Becton and Dickinson & Co, Mountain View, CA). An
isotype-matched mAb to unrelated antigen was used as a negative
control. The remaining cells were lysed, and ACE activity was
measured in the collected medium and the cell lysates using the
Fujirebio kit (Fujirebio Inc, Tokyo, Japan).
Immunological Characterization of the ACE Mutant (Plate
Immunoprecipitation Assay)
Plate immunoprecipitation assay was carried out as described
[34–35]. Briefly, 96-well plates (Corning, NY, USA) were coated
with anti-ACE mAbs via goat anti-mouse IgG (Pierce, Rockford,
IL) bridge and incubated for 3 hours with plasma samples. A panel
of mAbs directed against 16 different epitopes located on the N-
and C-domain of human ACE (‘conformational fingerprinting’)
was used. Binding of several of these anti-ACE mAbs to circulating
ACE is greatly influenced by dilution of the plasma/serum,
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because such dilution disturbs the equilibrium between ACE and
ACE-binding protein(s) in blood [Danilov 2012, unpublished
observations]. We therefore used as a comparator plasma samples
from individuals with equally elevated ACE levels (to allow
identical 1:50 dilutions), i.e., from patients with a truncation of the
C-terminal end of soluble ACE (W1197Stop, resulting in 1196
instead of the normal 1203 residues) [27], and from patients with a
mutation (Y456D) that also causes familial elevation of blood
ACE, but without a change in the C-terminal end of soluble ACE
[28]. ACE activity, precipitated from the blood to the bottom of
the wells by different mAbs, was measured by adding a substrate
for ACE (His-His-Leu) directly into the wells [34–35].
ACE Purification from Heparinized Plasma
ACE was isolated from plasma of 2 individuals with wild-type
ACE and 2 subjects harboring the IVS25+G.A mutation, using
affinity chromatography on a lisinopril-Sepharose column [36].
Briefly, plasma (4 mL) diluted 1:2 in HEPES (20 mmol/L,
pH 7.5, NaCl 150 mmol/L) was incubated with 5 mL of
lisinopril-Sepharose and after intensive washing of unbound
proteins, ACE was eluted with 50 mmol/L borate buffer, pH 9.5.
Western Blot Analysis of Mutant ACEs
All samples for SDS electrophoresis were equilibrated to a final
ACE activity 5 mU/mL (Hip-His-Leu as a substrate) and were run
using gradient 4–15% Tris-HCl pre-cast SDS PAGE gels (Bio-Rad
Laboratories, Hercules, CA). After electrophoretic transfer of
proteins to microporous Immobilon-P PVDF membranes, each
membrane was incubated in 10 mmol/L Tris-HCl (pH 8.0) buffer
containing 150 mmol/L NaCl, 0.05% Tween 20, and 5% dry
milk, prior to incubation with mAbs to denatured human ACE -
3C5 [37] and 5C8 [38] at a concentration of 2 mg/mL overnight
at 4uC. Subsequent steps were carried out with goat-anti-mouse
IgG conjugated with peroxidase (Jackson ImmunoResearch
Laboratories, West Grove, PA), and peroxidase activity was
developed using Amersham ECL Western Blotting Detection
Reagent (GE Healthcare, UK).
Genomic DNA Sequencing and Genotyping of the ACE
Gene
DNA and RNA extraction. Peripheral blood mononuclear
cells (PBMC) were isolated from whole blood of the siblings as well
as from the controls, using Ficoll HypaqueH. DNA was extracted
using the QIAampH DNA Blood Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol. The extract-
ed DNA was stored at 220uC until use. Total RNA was isolated
from PBMC with TRIzolH reagent (Invitrogen Life, Merelbeke,
Belgium) according to the manufacturer’s protocol and stored at
280uC until use.
DNA analysis. For each participant to the study, ACE gene
was screened for best known mutations by PCR amplification and
sequencing. In practice, the gene was screened for the insertion/
deletion of the Alu repeats within intron16 [39], the nonsense
1197th codon TGGRTGA mutation [27] and the missense 1199th
codon CCGRCTG mutation associated with the Pro1199Leu
substitution using primers as described [26].
This step was followed by amplification and subsequent
sequence analysis using primers pairs encompassing all the ACE
open reading frames (ORFs) and the exon-intron boundaries for
additional mutations (Table 1). The primers were designed against
the reference ACE gene sequence (AY436326) using the Primer3
software and purchased from Eurogentec (Seraing, Belgium). Taq
Gold DNA polymerase (Applied Biosystems, Nieuwekerke, The
Netherlands) was used for PCR amplification of 250 ng of
genomic DNA, using the following reaction mixture : 5 mL of
PCR buffer (10 mM Tris hydrochloride, pH 8.3 and 50 mM
potassium hydrochloride), 1.5 mM of MgCl2, 200 mM of each
deoxyribonucleoside triphosphate (dNTPs), 0.2 mM of each
primer in a final volume of 50 mL. Cycling conditions were as
follows: 5 min at 95uC; 30 cycles of 95uC for 40 s, 60uC for 40 s,
and 72uC for 1 min 20 s; and final extension of 7 min at 72uC.
The amplification was carried out in a Gene Amp PCR System
2700 (Applied biosystems). The resulting PCR products were
visualized on a 2% ethidium-bromide stained agarose gel. The
amplicons were then purified with Microcon (Amicon, Millipore
Corporation, Bedford, MA 01730 USA) columns and sequenced
in both orientations on an automated ABI 3130 capillary
sequencer (PRISM; Applied Biosystems, Nieuwerkerk, the Nether-
lands), using the Big Dye Deoxy Terminator Cycle Sequencing kit
from the same manufacturer.
Detection of the IVS25+1G.A mutation using Restriction
Length Fragment Polymorphism Analysis is described in the Data
S1 and Table S1.
Transcript analysis. In order to perform ACE transcript
analysis, 1.0 mg of total RNA extracted from PBMC of the 16
people from the two unrelated families and from controls were
digested with 1.U of DNAse I (Invitrogen, Merelbeke, Belgium) in
10 mL of a mix containing 20 mmol/L Tris-HCl, pH 8.4,
2 mmol/L MgCl2 and 1 U/mL of RNase-Inhibitor (Roche,
Boehringer Mannheim, Germany) during 15 min at 25uC. The
reaction was stopped by adding 1 mL of EDTA 25 mmoles/L.
After denaturation at 70uC during 10 min, 1.0 mg of ice-chilled
total RNA was reverse-transcribed with 1 mL of random hexamers
(0.7 mmol/L; Eurogentec; Belgium), 4 U/mL of SuperscriptTM
RNase H2 reverse transcriptase (Invitrogen, Merelbeke, Belgium),
0.35 mmol/L dNTPs, 50 mmol/L Tris-HCl, pH 8.3, 75 mmol/L
KCl, 3 mmol/L MgCl2 and 100 mmol/L dithiothreitol, in a final
volume of 50 mL. The cDNA synthesis was performed at 42uC for
1 h.
PCR amplification of the cDNA from 24th to 26th intron was
carried out on 2 mL RT product in a final volume of 50 mL, using
primers ACE2425-F and ACE2425-R (Table 2). The amplifica-
tion, visualization and subsequent sequence analysis were carried
out as described above.
In silico Prediction Analysis
Bioinformatics analysis of potential splicing aberration was done
using different Web-based programs designed to detect putative
splice sites, taking into account branch points, exonic and intronic
motifs, and several regulatory proteins.
N Splice Scan II (http:/www.splicescan2.lumc.edu) [40].
N CRYP-SKIP (http:/www.dbass.org.uk/cryp-skip) [41].
Results
Clinical Data
First pedigree. The index patient, a 41-year-old Caucasian
female was referred in November 2006 to the Internal Medicine
Department of the Cliniques Universitaires Saint-Luc because of
fatigue and headache persisting for several months, as well as of
incidentally found plasma ACE level far above the normal range
(492 IU/L with the ACE kinetic kit, normal range: 8–52 IU/L).
The patient had neither relevant past medical history nor other
complaints and did not take any medication. Blood pressure on
admission was 110/70 mmHg. Besides few infracentimetric
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cervical lymphadenopathies, clinical examination was unremark-
able. Determination of ACE activity after another blood sampling
from this index patient with ACE colorimetric kit confirmed the
high level of circulating ACE (146 IU/L), more than five times the
upper limit of the assay (normal range 8–26 IU/L). Electrocar-
diogram and echocardiography were normal and, in particular,
there was no evidence of left ventricular hypertrophy. A thorough
work-up, including detailed blood and urine analysis and total
body FDG-PET scan allowed to rule out sarcoidosis or other
granulomatous diseases. By the end of the work-up, the symptoms
had improved spontaneously.
Due to very high elevation of blood ACE level (much higher
that in the case of sarcoidosis or Gaucher diseases [23,24],
comparable with blood ACE levels characteristic for ACE
mutations [26–28] the hypothesis of a familial elevation of
circulating ACE level was considered. ACE levels were determined
in the siblings (median age: 44 years, range 26–49 years) and the
13 year-old daughter of the index patient. Circulating levels of
ACE differ 3-fold in the normal population [22,42]. Therefore, in
order to estimate correctly the effect of the mutation on ACE
levels, it is more appropriate to compare the level of blood ACE in
a given patient to members of his/her family, than to upper level
of normal range. A 8–16-fold increase in plasma ACE activity was
found in 7 out of 9 tested subjects (Figure 1A). The hyper-ACE
segregation pattern was compatible with autosomal dominant
inheritance. All subjects with elevated circulating ACE were
normotensive at the time of clinical assessment. However, three of
the them (II.1, II.8 and II.10), aged 49, 41 and 26 year-old were
taking an antihypertensive drug (a fixed combination of lisinopril
20 mg and hydrocholorothiazide 12.5 mg, bisoprolol 5 mg, and
Table 1. Primers used for PCR amplification of the exons and exon-intron boundaries of the ACE gene (accession number
AY436326).
Name Sequence (59-.39) Position Expected amplicon size (bp)
ACE1-FOR GGGGGTGTGTCGGGTT 2296–2311 253
ACE1-REV TCGGCGCTGGAGTTGTA 2532–2548
ACE2-FOR CCTTTATGGCCTGCATCTA 3151–3170 1285
ACE2-REV GGGCAATGTGGGAACACT 4417–4435
ACE3-FOR GTGAAGGCCGTTGAAGACT 4986–5004 865
ACE3-REV ACTTCCGTGGGACTCATG 5832–5850
ACE4-FOR ACTCAGCGATGCATGAAGAA 6301–6320 743
ACE4-REV AGAACGTGCTCTTCCCATGT 7026–7045
ACE5-FOR TGTCTTTCAGGTGCCAATC 7658–7676 332
ACE5-REV CCTCTCAGCCCTCCCATA 7972–7989
ACE6-FOR TTCCCTCTCCTTTCATCTCA 8279–8298 1060
ACE6-REV CATCAGAGCAGCCAGACA 9321–9338
ACE7-FOR GCCCATGGTACCCACTCT 9584–9601 1131
ACE7-REV GGGACAGCATCTCTGTGTGT 10696–10715
ACE8-FOR AGCCCTCAGCTCCCACTT 11753–11770 632
ACE8-REV CTCACTCAGCCTGCACAT 12366–12384
ACE9-FOR CAAGCAGAGGTGAGCTAAGG 13878–13897 585
ACE9-REV CACTGTGGTCCGTCTTTACC 14442–14461
ACE10-FOR GAGGGCATTGAGCCTAAGTA 16171–16190 562
ACE10-REV GACCCTTTGCTTGGTTCAT 16715–16733
ACE11-FOR CACTGTCCTCTCCCAACAC 18672–18690 1135
ACE11-REV ACACAAAGCTGTGGGTACTG 19787–19806
ACE12-FOR AAGGCCCTCAACCAACTC 21626–21643 680
ACE12-REV GTTAAGACCCAAGGCTGGAG 22286–22305
ACE13-FOR CATGCTGTCTCCTTGCTT 22391–22408 262
ACE13-REV GTCACCTCAGGAGTGTCTCA 22634–22653
doi:10.1371/journal.pone.0059537.t001
Table 2. Primers used for PCR amplification of the ACE cDNA (NM_000789.3) region encompassing the IVS25 splice-junction site.
Name Sequence (59-.39) Position Expected amplicon size (bp)
ACE2425-FOR GTGCCTTACATCAGGTACTTTGT 3401–3423 561
ACE2425-REV GTCACCTCAGGAGTGTCTCA 3942–3961
doi:10.1371/journal.pone.0059537.t002
New Splicing ACE Mutation
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e59537
telmisartan 80 mg, respectively). The youngest (II.10) suffered
from chronic kidney disease with stage 4 renal insufficiency
probably favored by neonatal hypoxia and hypoplasia of the right
kidney. The five other subjects harboring the mutation were
normotensive without treatment and had no evidence of overt
cardiovascular or renal disease. Electrocardiogram (n= 5) and
echocardiography (n = 2) showed no evidence of left ventricular
hypertrophy or other significant abnormality. Plasma potassium
(mean: 3.9 mEq/l, range: 3.8–4.3 mg/dl) and, with the exception
of II.10, plasma creatinine (mean: 0.84 mg/dl, range: 0.74–
1.14 mg/dl), glomerular filtration assessed by the MDRD formula
(mean: 86 range: 69–115 ml/min/1.73 m2), as well as urine
protein-to-creatinine ratio (mean: 55 mg/g; range: 0–119 mg/g)
were all within normal limits.
Second pedigree. In 2005, an otherwise asymptomatic 55-
years old Caucasian female patient with a past history of Grave’s
disease presented with a left facial hemispasm. Clinical examina-
tion was otherwise unremarkable. She was normotensive and had
no left ventricular hypertrophy on echocardiography. A determi-
nation of plasma ACE level was asked in order to rule out a
granulomatous disease. The latter was found to be dramatically
increased (339 IU/L with ACE kinetic kit and normal range 12–
68 IU/L). A comprehensive work-up including blood and urine
analysis, CT-scan and Gallium-67 scintigraphy failed to show
evidence of sarcoidosis, tuberculosis or another granulomatous
disease. Subsequently, the patient was offered yearly thorax CT-
scan which remained negative, whereas plasma ACE was
consistently in the range of 330–360 IU/L.
Two of four paternal first-degree cousins of the index patient,
aged 59 and 66 years, also had a marked elevation of circulating
ACE (Figure 1B). Interestingly, the first cousin (II.6) had been
treated with corticosteroids for sarcoidosis at the age of 46. The
diagnosis was based on serendipitous finding of pulmonary
interstitial pattern, associated with increased lymphocytosis at
broncho-alveolar lavage and markedly elevated circulating ACE
levels. No biopsy was performed. While interstitial lesions on chest
X-ray and computed tomography were in favor of an advanced
form of sarcoidosis, the patient had no respiratory symptoms and
carbon monoxide diffusion was only minimally altered. Based on
disappearance of the radiologic interstitial syndrome, the patient
was considered as cured despite a persistent increase in circulating
ACE levels. Of note, by that time (in 1999) the first publication
describing a mutation in ACE causing elevation of blood ACE was
not reported [26]. However two papers identifying familial
elevation of blood ACE levels in Japan [43] and Italy [44] had
already been published.
To the best of our knowledge, the two pedigrees are unrelated.
While the father and mother of the first sibship came from
Tournai (province of Hainaut, French-speaking southwest part of
Belgium) and Deinze (province of East Flanders, Flemish northeast
part of Belgium), respectively, the second pedigree was originally
from Jalhay (Province of Lie`ge, French-speaking southeast part of
Belgium).
Response to Captopril
In the first pedigree, 50 mg captopril was given orally to the
index patient, her daughter, her husband and 5 siblings. II.1 and
II.10 were excluded because they already took RAS blockers.
Baseline renin (764 vs. 961 ng/L), prorenin (47616 vs.
46618 ng/L), angiotensinogen (22326963 vs.
357561812 nmol/L), Ang I (763 vs. 861 pmol/L), Ang II
(662 vs. 861 nmol/L), and aldosterone (48632 vs. 2761 ng/L)
levels were similar in affected (n = 6) and non-affected (n = 2)
family members. Furthermore, with the exception of Ang I, the
captopril-induced changes in RAAS components (2 to 3-fold rises
in renin, 2 to 3-fold decreases in Ang II and aldosterone, and no
change in prorenin or angiotensinogen) were identical in both
groups (Figure 2). Ang I rose in parallel with renin in the non-
affected family members only.
Flow Cytometry of Dendritic Cells with Anti-ACE mAbs
and ACE Shedding
FACS analysis of dendritic cells demonstrated that affected
family members with the IVS25+1G.A mutation expressed a
<50% lower level of ACE on their cell surface versus non-affected
family members (Figure 3A). In line with this observation, the
cellular (membrane-bound) ACE activity levels in dendritic cells
from affected family members were lower, while their medium
(soluble) ACE levels were higher, which resulted in an at least 3-
fold increase of ACE shedding in affected versus non-affected
family members (Figure 3B).
DNA Sequence Analysis
Genetic analysis of the ACE gene was performed in both
families. While genetic screening for previously described muta-
tions in ACE gene proved negative, a new heterozygous splice site
mutation in the first nucleotide in GT dinucleotide-canonical 59
donor splice site of intron 25 (IVS25+1G.A) was identified in
both index patients and subsequently found to cosegregrate with
elevated circulating ACE in all available relatives (Figure 1A and
1B). The intron 16 insertion/deletion (I/D) polymorphism [39]
was present in both families. D/D, D/I and I/I genotypes were
found in five, nine and two subjects, respectively and not assessable
in two family members (Figure 1 A–B).
Possible Mechanisms of Transmembrane Anchor
Elimination
Mutations affecting human splice sites can lead to two major
phenotypes, the exon skipping and activation of the cryptic
splice sites of the same type located nearby of affected splice
sites [41]. In silico analysis of the ACE gene (Data S1, Figures
S1, S2, S3) demonstrates that the IVS25+1G.A
(c.3691+1G.A) mutation can lead to three possible scenarios:
i) skipping of 25th exon; 2) full retention of 25th intron; 3)
generation of aberrant cryptic 59donor site. In all three
scenarios a Premature Termination Codon will be generated,
leading to deletion of the transmembrane anchor.
Immunological Characterization of the Mutant ACE
A panel of mAbs directed against 16 different epitopes
located on the N-and C-domain of catalytically active human
ACE was used to characterize the conformation of ACE from
affected family members (conformational fingerprinting’; Fig. 4A).
Among these mAbs, 1B3 recognizes an epitope on the stalk
region of ACE coded by exon 25 [38]. Its binding decreases in
the case of a truncation of the C-terminal end of soluble ACE
(W1197X) [27], but not in patients with a mutation (Y456D)
that causes familial elevation of blood ACE without a change in
the C-terminal end of soluble ACE [28]. Importantly, binding
of this antibody to blood ACE from carriers of the
IVS25+1G.A mutation was dramatically higher as compared
to both W1197X and Y465D ACE, thereby ruling out scenario
1. In full agreement with this observation, binding of the mAbs
1B8 and 3F10 (which recognize the truncated ACE of W1179X
carriers [27]) was lower in our affected family members versus
W1197X ACE, but not versus Y465D ACE. These data
indicate that the mutated ACE from the index patient still
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Figure 1. Genealogic tree of the two families harboring the IVS25+1G.A mutation. Genealogic tree of the two Belgian families harboring
the IVS25+1G.A mutation, showing the circulating ACE levels and the genotypes at the IVS25+1 and I/D loci. Circulating ACE was determined with
New Splicing ACE Mutation
PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e59537
contains exon 25, and is immunologically different from
previously described mutated ACEs.
Western blotting of ACE purified from the sera of 2 subjects
carrying the IVS25+1G.A mutation and of two non-carriers,
making use of mAb 3C5, which recognizes a sequential epitope at
the beginning of the C-domain [45], and mAb 5C8, which
recognizes an epitope at the C-terminal end of soluble ACE coded
by exon 25 [27,38], showed no size difference between soluble
ACE from carriers and non-carriers (Figure 4B). However, the
5C8/3C5 ratio for ACE purified from sera of carriers (which will
contain a mixture of mutant and wild-type ACE) was significantly
higher than that of normal ACE. This further supports that
skipping of exon 25 did not occur in carriers of the IVS25+1G.A
mutation.
mRNA and cDNA Analysis from Subjects Carrying
IVS25+1G.A ACE Mutation
ACE cDNA analysis (after mRNA isolation and reverse
transcription) from patients with the IVS25+1 G.A mutation in
ACE gene provided definite evidence for the mechanism of
transmembrane anchor elimination as a result of this mutation.
PCR amplification of the regions flanking this mutation generated
two ACE amplicons of 561-bp and 712-bp using cDNA from
carriers of this mutation, whereas only the 561-bp amplicon was
present in the normal subjects (Figure 5). Sequence analysis from
both 561- and 712-bp amplicons revealed that the IVS 25+1 G.A
mutation was present in the 712-bp fragment. The scheme
presented in Figure S3 demonstrated that the appearance of the
712 amplicon could be only due to retention of 25th intron.
Therefore, we can state that this mutation resulted in the loss of
the GT consensus splice donor site and a subsequent retention of
the Fujirebio kit in the individuals of the first pedigree (1A) except II.1, and with the ACE kinetic kit in individual II.1 of the first pedigree and in all
individuals of the second pedigree (1B). This explains the higher values in individual II.1 compared to his siblings in the first pedigree. Arrow: index
patient. NA: not analyzed; WT: wild type; Mut: presence of the IVS25+1 G.A mutation at the heterozygous state; I, insertion; D, deletion.
doi:10.1371/journal.pone.0059537.g001
Figure 2. Plasma values of renin-angiotensin-aldosterone system components at baseline and after captopril. Plasma values of renin-
angiotensin-aldosterone system components at baseline and after oral intake of 50 mg captopril at t = 0 in 6 affected and 2 unaffected family
members. Aogen: angiotensinogen; Ang: angiotensin.
doi:10.1371/journal.pone.0059537.g002
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151-bp from intron 25 within the mRNA variant (accession
number: provisional submission ID1529627), as predicted accord-
ing to scenario 2. This frameshifted ACE mRNA splice variant
leads to the appearance of a premature stop codon at position
3763, hence a premature termination of the protein.
Discussion
Several molecular mechanisms underlying familial increases of
circulating ACE have been described in the past decade. The
Pro1199Leu substitution in the stalk region of ACE protein
[26,46] was found to be associated with a 5-fold increase in serum
ACE activity in the blood of affected individuals from the
Netherlands [26], Germany [47], and USA [48], in the absence of
any clinical abnormality [26]. It has been suggested that this
substitution leads to better accessibility of the cleavage site in the
stalk region for ACE secretase, thus enhancing the cleavage
secretion process [26,46].
Then, a nonsense mutation at the codon for Trp1197
(TGGRTGA) identified in siblings was associated with a dramatic
increase (13-fold) in circulating ACE level [27]. As a result, half the
ACE expressed in these patients had a length of 1196 amino acids
Figure 3. Cell surface expression and shedding of mutant ACE. Panel A. FACS analysis of immature dendritic cells with anti-ACE
antibodies. Cells were stained with mAb i2H5 (black histogram) or with control mouse IgG (grey histogram). Figures correspond to values of median
fluorescence intensity. Affected family members with the IVS25+1G.A mutation were shown to express a <50% lower level of ACE on their cell
surface compared to non-affected family members. Panel B. ACE shedding into the medium. ACE activity in the medium (‘‘Soluble ACE’’) and
membrane-bound ACE activity were determined on immature dendritic cells from 2 subjects harboring the IVS25+1G.A mutation (II.7 and III.1) and
2 controls (II.6 and I.9) from the first pedigree. Their ratio represents the rate of ACE shedding into the medium. In agreement with the findings of the
FACS analysis, shedding was <3 times larger in the individuals with the mutated ACE. WT: wild-type subjects.
doi:10.1371/journal.pone.0059537.g003
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and lacked the transmembrane anchor, which starts from Val1228
[16]. Previous studies have shown that different recombinant ACE
mutants also lacking the transmembrane anchor are not trafficked
to the cell membrane but are directly secreted into the circulation
[18,49]. Interestingly, Y465D substitution in the N domain of
ACE (far from the stalk region) was also associated with familial
elevation of blood ACE. In this case the increase in ACE shedding
depended on alterations in ACE dimerization [28].
We report here a novel splice site mutation of intron 25 -
IVS25+1G.A - cosegregating with a 10-fold elevation of plasma
Figure 4. Analysis of the mutant ACE protein. Panel A. Conformational fingerprinting of mutant ACEs with a set of mAbs to ACE.
Values were normalized versus individuals with the Trp1197Stop mutation or the Tyr465Asp mutation, since their blood contained similarly elevated
ACE levels and allowed measurements at the same dilution. *P,0.05 vs. 100%. Panel B., Western blot analysis of wild-type (WT) and mutant
ACEs. Insert, 5C8/3C5 density ratio. *P,0.05 vs. WT.
doi:10.1371/journal.pone.0059537.g004
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ACE in two Belgian pedigrees (see Data S1, Table S2). As
demonstrated by cDNA analysis, the latter leads to intron 25
retention, frameshift and premature stop codon upstream of the
transmembrane domain of ACE.
The intron 25 - IVS25+1G.A variant is expected to yield a
shorter ACE protein (1213 instead of 1306 amino acid residues)
modeled at its C-terminal domain (see Data S1, Analysis in silico).
This remodeling consists of the loss of the C-terminal 76 amino
acids of the normal ACE protein and the addition of 12 novel
aminoacids to the C-terminal protein end. Translation of this
abnormal mRNA produces indeed a truncated ACE protein
consisting of the Leu-1 to Ser-1201 expected amino acid stretch
completed by a novel Asp-Thre-Ala-Thre-His-Pro-Thre-Ser-Ser-
Leu-Gly-Ser stretch at its C-terminal end. Accordingly, the loss of
the C-terminal domain harboring the Val-1228-to-Ser-1248
transmembrane domain likely leads to a direct shedding of the
remodeled ACE into the circulation, hence contributing to the
observed high level of circulating ACE in mutation carriers.
In agreement with these findings, in vitro analysis disclosed a
50% decrease in surface ACE expression in DC derived from
patients harboring the mutant ACE, combined with a 3-fold
increase in ACE shedding in comparison with non-affected
members, and an altered ‘‘conformational fingerprinting’’ binding
pattern of the mutated ACE to a panel of ACE antibodies.
As was the case for the Pro1199Leu substitution [26], this new
mutation was associated neither with RAAS activation nor with a
different responsiveness to ACE inhibition. Furthermore, no
related cardiovascular damage could be demonstrated. These
data are consistent with the hypothesis that membrane-bound
ACE is exclusively responsible for Ang II generation and its
cardiovascular consequences.
Of note, point mutations affecting the 59donor splice-site, as
identified in the current study, are rather common [50]. At this
donor site, the most common mutations are those affecting the G
residue at position +1, followed by mutations at position +5. Each
of both donor site variants are thought to significantly reduce the
pairing of the donor splice site with the complementary site in the
small nuclear ribonucleoprotein particle U1snRNP, which is one
of the first steps in the complex process of mRNA splicing [51].
Consequently, mutations at donor sites can either lead to exon
skipping, as predicted in ten different IVS+1 mutations within the
RB1 gene and confirmed in vitro [50] or intron retention, as found
in this work. A complex combination of insertion and deletion can
also occur through activation of a cryptic splice site [50,52].
In conclusion, comparative analysis of ACE protein and nucleic
acids (genomic DNA, and cDNA) demonstrates unambiguously
that the novel IVS25+1G.A splice site mutation is associated with
retention of intron 25 within ACE mRNA. However, the
normotensive status of carriers of this novel mutation shows
evidence that high circulating serum ACE is not associated with
hypertension. These data are consistent with the hypothesis that
membrane-bound rather than secreted ACE is responsible for Ang
II generation and its cardiovascular consequences. Indeed,
transgenic mice expressing a form of ACE lacking the transmem-
brane domain (i.e., having soluble ACE only) are phenotypically
similar to ACE-deficient mice [53].
Despite its absence of functional relevance or associated
phenotype, the identification of a new mutation associated with
a major increase of circulating ACE is of substantial clinical
importance, as it will contribute to make a clear distinction
between granulomatous diseases (namely sarcoidosis) and hyper-
ACE-emia due to mutations (in this particular case, due to lack of
transmembrane domain), thus preventing false diagnosis [47],
unnecessary work-up [54] and long-term immunosuppressive
treatment [47].
It should also be pointed out that the clinical features of the two
index patients did not warrant ordering an ACE protein level.
However, if analysis of human serum ACE is requested in the
absence of any clear indication and if huge elevations are found as
in the ACE mutations discovered so far, we would recommend
Figure 5. Analysis of cDNA from subjects harboring the IVS25+1G.A mutation versus controls. cDNA analysis of PCR products resulting
from the amplification of cDNA from subjects harboring the IVS25+1G.A mutation versus wild type controls, visualised after electrophoresis on a 2%
ethidium-bromide stained agarose gel. Ladder; Lanes 2–3: No Template Control (NTC); Lanes 4–5: two wild-type subjects for the IVS25+1G.A
mutation; Lanes 6–9 : subjects heterozygous for the IVS25+1G.A mutation.
doi:10.1371/journal.pone.0059537.g005
New Splicing ACE Mutation
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e59537
considering a genetic analysis of ACE, rather than an extensive
work-up directed at diseases that are known to increase ACE.
Supporting Information
Figure S1 In silico analysis of the IVS25+1G.A mutation of
ACE. A. A screenshot of the SpliceScan II output. Prediction for
the wild type (exon 24-exon 26) contains the blue rectangle that
schematically represents exon 25 with flanking 59 (circle) and 39
(triangle) splice sites. The X-axis indicates the location of the
predicted exons along with splicing signals relative to the
beginning of the fragment containing exon 25 surrounded by
6300nt intronic flanks. Mutation IVS25+1G.A converts the
most significant dinucleotide GT to AT in the 59 splice site thus
removing the splice site out of the pool of available canonical 59
splice sites flanking exon 25. Since none of the 59splice sites
predicted by the Bayesian splice sites sensor are located in the
vicinity of the original 25th exon 39 flank, the predicted effect of the
IVS25+1G.A mutation is exon skipping (no rectangle shown as
result of mutation), i.e. there is no splicing-competent exon
predicted in this region. B. A screenshot of the CRYP-SKIP
output. Probability of cryptic splice site activation (PCR-E) found by
the multivariate logistic discrimination procedure is shown on the
right as a pointer balancing between exon skipping (EXSK) and
cryptic splice site activation (CR-E). PCR-E is shown on the right
as a pointer balancing between exon skipping (EXSK) and cryptic
splicesite activation (CR-E). Values of each predictor variable used
in the regression model are shown on the left where the last table
row indicates PCR-E value of for the input sequence. Exon 25
sequence is in upper case and flanking introns 24 and 25 are in
lower case. The program takes as input the wild type internal exon
with some intronic flanks and evaluates chances of the same type
cryptic splice sites activation located nearby of the original sites in
case of a mutation eliminating the most significant GT/AG
dinucleotides in the canonical 59/39 splice sites. Two predicted
aberrant 59 splice sites are shown as red arrows, with their
corresponding normalized relative strength of 0.17 and 0.35. The
blue triangle stands for the cryptic 39 splice site that could
potentially be activated in case of mutation affecting original 39
splice site. The aberrant splice sites have been predicted by the NN
Splice method (http://www.fruitfly.org/seq_tools/splice.html).
(TIF)
Figure S2 Premature Termination Codon Creation. Possible
scenarios of the appearance of the Premature Termination Codon
(PTC) as a result of IVS25+1G.A mutation in ACE. Fragment of
the genomic DNA sequence. Exonic sequences were highlighted
by yellow. Substitution of 1st nucleotide in 25th intron (G) by A
shown by red color and underlined. B. PTC as a result of 25th
exon skipping. C. PTC as a result of full retention of 25th intron.
D. PTC as a result of aberrant 59donor splice site and partial
retention of 25th intron. Part of the exonic sequence (25th and 26th
exons) are in upper case and parts of the flanking intron (25th) are
in lower case. Putative PTCs are highlighted in red. Non-ACE
protein sequences are highlighted in blue.
(TIF)
Figure S3 Fragment of the genomic DNA sequence. Exonic
sequences (24th–26th exons) were highlighted by yellow. Substitu-
tion of 1st nucleotide in 25th intron (G) by A is shown by red color
and underlined. Sequences of the primers that were used for
amplification of intron-exon boundaries were highlighted with
green. Amplification of cDNA (derived from mRNA) from subjects
with wild type ACE (with normal level of blood ACE) gave band
561 bp. In the case of retention of 25th intron an additional band
of 712 bp appeared. Putative PTC was highlighted by red.
(TIF)
Table S1 Restriction Length Fragment Polymorphism Analysis
of IVS25+1G.A mutation.
(DOC)
Table S2 Fold-change computation of ACE serum level
according to genetic status of the patients.
(DOC)
Data S1 Includes in silico analysis of mutant ACE protein, RFLP
identification of IVS25+1G.A ACE mutation and fold-change
computation of ACE serum level according to genetic status of
patients.
(DOC)
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